文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

局部麻醉药持续切口输注预防胸骨正中切开体外循环心脏术后肺炎:STERNOCAT随机临床试验

The effect of local anesthetic continuous wound infusion for the prevention of postoperative pneumonia after on-pump cardiac surgery with sternotomy: the STERNOCAT randomized clinical trial.
PubMed 文献 · Intensive Care Med · 2019-01-07
一句话结论胸骨正中切开体外循环心脏术后,L-布比卡因持续切口输注未能降低肺炎发生率,作者认为这些发现不支持该适应证的局部麻醉药持续切口输注。

STERNOCAT是一项在五个学术中心开展的双盲、安慰剂对照随机试验,纳入2012年2月至2014年11月接受胸骨正中切开体外循环心脏手术的患者,术后经胸骨前多孔导管48小时输注L-布比卡因(10 ml/h,12.5 mg/h)或安慰剂(生理盐水),随访30天。主要终点为研究期间(至出院或30天)肺炎发生率,假设降低30%。1439例完成试验,L-布比卡因组肺炎36/746例(4.9%),安慰剂组42/739例(5.7%),校正中心和基线肺炎风险的绝对风险差为-1.3%(95%CI -3.4; 0.8),P=0.22。在预先定义的高危患者亚组中,L-布比卡因降低了肺炎发生率(绝对风险差-5.6% [95%CI -10.0; -1.1],P=0.01)。作者认为这些发现不支持该适应证的局部麻醉药持续切口输注,并建议进一步研究其在高危患者中的效果。

要点

  • 在1493例随机、1439例完成试验的胸骨正中切开体外循环心脏手术患者中,L-布比卡因组肺炎36/746例(4.9%)vs 安慰剂组42/739例(5.7%),校正中心和基线风险的绝对风险差-1.3%(95%CI -3.4; 0.8),P=0.22。
  • 在预先定义的高危患者亚组中,L-布比卡因降低肺炎发生率(绝对风险差-5.6% [95%CI -10.0; -1.1],P=0.01)。
  • 作者结论认为,胸骨正中切开心脏术后L-布比卡因持续切口输注未能降低肺炎发生率,这些发现不支持该适应证的局部麻醉药持续切口输注。
  • 作者建议进一步研究应探讨其在高危患者中的效果。

适用人群与场景

  • 接受胸骨正中切开和体外循环(CPB)心脏手术的患者,于2012年2月至2014年11月纳入,随访30天。

处置流程与药物剂量

  • 术后经胸骨前多孔导管48小时输注L-布比卡因(10 ml/h,12.5 mg/h)或安慰剂(生理盐水);麻醉和镇痛方案标准化。

研究设计与关键结果

  • 研究类型:随机、双盲、安慰剂对照试验,在五个学术中心开展,1493例随机、1439例完成试验。
  • 主要终点:研究期间(至出院或30天)肺炎发生率,L-布比卡因组36/746例(4.9%)vs 安慰剂组42/739例(5.7%),校正中心和基线肺炎风险的绝对风险差-1.3%(95%CI -3.4; 0.8),P=0.22,未达统计学显著。
  • 预先定义的高危患者亚组:L-布比卡因降低肺炎发生率,绝对风险差-5.6%(95%CI -10.0; -1.1),P=0.01。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照试验(STERNOCAT),EudraCT Number: 2011-003292-10;Clinicaltrials.gov Identifier: NCT01648777。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:胸骨正中切开心脏术后L-布比卡因持续切口输注未能降低肺炎发生率,这些发现不支持该适应证的局部麻醉药持续切口输注。
  • 作者建议:进一步研究应探讨其在高危患者中的效果。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Postoperative pain after cardiac surgery, exacerbated by cough and sternal mobilization, limits clearance of bronchopulmonary secretions and may predispose to postoperative pneumonia. In this study, we tested the ability of local anesthetic continuous wound infusion to prevent pneumonia after cardiac surgery with sternotomy and cardiopulmonary bypass (CPB) owing to better analgesia and bronchopulmonary drainage.

METHODS: In this randomized, double-blind, placebo-controlled trial conducted in five academic centers, patients undergoing cardiac surgery with sternotomy and CPB were enrolled from February 2012 until November 2014, and were followed over 30 days. Patients were assigned to a 48-h infusion (10 ml h-1) of L-bupivacaine (12.5 mg h-1) or placebo (saline) via a pre-sternal multiperforated catheter. Anesthesia and analgesia protocols were standardized. The primary end point was the incidence of pneumonia during the study period, i.e., until hospital discharge or 30 days. We hypothesized a 30% reduction in the incidence of pneumonia.

RESULTS: Among 1493 randomized patients, 1439 completed the trial. Pneumonia occurred in 36/746 patients (4.9%) in the L-bupivacaine group and in 42/739 patients (5.7%) in the placebo group (absolute risk difference taking into account center and baseline risk of postoperative pneumonia, - 1.3% [95% CI - 3.4; 0.8] P = 0.22). In the predefined subgroup of patients at high risk, L-bupivacaine decreased the incidence of pneumonia (absolute risk difference, - 5.6% [95% CI - 10.0; - 1.1], P = 0.01).

CONCLUSIONS: After cardiac surgery with sternotomy, continuous wound infusion of L-bupivacaine failed to decrease the incidence of pneumonia. These findings do not support the use of local anesthetic continuous wound infusion in this indication. Further study should investigate its effect in high-risk patients.

TRIAL REGISTRATION: EudraCT Number: 2011-003292-10; Clinicaltrials.gov Identifier: NCT01648777.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Amour J, Cholley B, Ouattara A, et al. The effect of local anesthetic continuous wound infusion for the prevention of postoperative pneumonia after on-pump cardiac surgery with sternotomy: the STERNOCAT randomized clinical trial. Intensive Care Med. 2019. PMID: 30617461. doi:10.1007/s00134-018-5497-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。